Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3444597 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 | |
| SCHEMBL13107918 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 | |
| SCHEMBL6379708 | 0.82 | CYP1A2 (0.57) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 | |
| SCHEMBL6379710 | 0.82 | CYP1A2 (0.57) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 | |
| SCHEMBL7118032 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 | |
| SCHEMBL13009931 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 | |
| SCHEMBL7118034 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 | |
| SCHEMBL6377003 | 0.78 | ATM (0.48) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 | |
| SCHEMBL15786315 | 0.77 | CYP19A1 (0.45) | CYP1A2CYP2D6HSD17B10LMNAL3MBTL1 | |
| SCHEMBL11618260 | 0.77 | CYP1A2 (0.57) | CYP1A2CYP2D6HSD17B10LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816533-B2 | Asymmetric imine hydrogenation processes | ABDUR-RASHID KAMALUDDIN | 2010-10-19 | — | — | US | disclosed |
| US-20070293681-A1 | Asymmetric Imine Hydrogenation Processes | ABDUR-RASHID KAMALUDDIN | 2007-12-20 | — | — | US | disclosed |
| EP-1086941-B1 | PROCESS FOR PREPARING REDUCTANTS OF UNSATURATED ORGANIC COMPOUNDS BY THE USE OF TRICHLOROSILANE AND REDUCING AGENTS | TOKUYAMA CORP (JP) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005056513-A1 | ASYMMETRIC IMINE HYDROGENATION PROCESSES | ABDUR-RASHID KAMALUDDIN (CA) | 2005-06-23 | — | — | WO | disclosed |
| US-6420613-B1 | CHEMICAL REDUCTION WITH TRICHLOROSILANE | TOKUYAMA CORPORATION (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1086941-A1 | PROCESS FOR PREPARING REDUCTANTS OF UNSATURATED ORGANIC COMPOUNDS BY THE USE OF TRICHLOROSILANE AND REDUCING AGENTS | TOKUYAMA CORPORATION (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293681-A1 | Asymmetric Imine Hydrogenation Processes | HRH3, HRH1, HRH4 | CYP1A2 436/4885CYP2D6 631/4885HSD17B10 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.